Photo by cdc from unsplash
Nyffenegger and colleagues report that blocking ferriportin with vamifeport reduces hemolysis in a murine model of sickle cell disease (SCD). Vamifeport reduces intracellular iron and induces iron-limited hematopoiesis. Since a… Click to show full abstract
Nyffenegger and colleagues report that blocking ferriportin with vamifeport reduces hemolysis in a murine model of sickle cell disease (SCD). Vamifeport reduces intracellular iron and induces iron-limited hematopoiesis. Since a small decrease in the intracellular sickle hemoglobin concentration has a marked impact on the delay time for sickling, reducing sickle hemoglobin decreases sickling and hemolysis. In addition, vamifeport also reduces adhesion molecule expression, decreasing inflammation. This supports further development of vamifeport as a novel therapy for SCD.
Journal Title: Blood
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!